Paper Details

  1. Home
  2. Paper Details

Once-daily Mesalamine Formulation for Maintenance of Remission in Ulcerative Colitis: A Randomized, Placebo-controlled Clinical Trial.

Author: BarrettAndrew C, BorteyEnoch, ForbesWilliam P, GordonGlenn L, LichtensteinGary R, MurthyUma, PatersonCraig, PruittRonald, SedghiShahriar, ZakkoSalam

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Mesalamine granules 1.5 g once daily were efficacious and safe for the maintenance of ulcerative colitis remission.
Paper Details　
Original Abstract of the Article :
GOALS: To evaluate the efficacy and safety of mesalamine granules 1.5 g once daily for maintenance of ulcerative colitis (UC) remission. BACKGROUND: Mesalamine is a first-line treatment for induction and maintenance of UC remission. STUDY: A phase 3, randomized, double-blind, placebo-controlled tr...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1097/MCG.0000000000000414

データ提供：米国国立医学図書館（NLM）

Mesalamine for Ulcerative Colitis: A Camel's Perspective on Remission Maintenance

This study evaluates the efficacy and safety of [mesalamine granules] once daily for the [maintenance of remission] in [ulcerative colitis (UC)]. The researchers conducted a [randomized, double-blind, placebo-controlled trial] and found that [mesalamine] was significantly better than [placebo] in maintaining [UC remission] at 6 months. They also observed that [mesalamine] was well-tolerated, with [adverse events] occurring at a rate similar to [placebo].

A Camel's Journey: Seeking Remission for Ulcerative Colitis

This study offers hope for individuals with [UC] seeking to maintain [remission]. The once-daily [mesalamine] formulation provides a convenient and effective way to manage the condition and prevent [relapse].

Managing Ulcerative Colitis: A Camel's Advice

If you have [UC], working closely with your doctor to develop a personalized treatment plan is essential. This may involve medication, lifestyle changes, or other therapies depending on your individual needs.

Dr.Camel's Conclusion

This study demonstrates the efficacy and safety of once-daily mesalamine granules for maintaining remission in ulcerative colitis. The findings suggest that this convenient formulation can be an effective option for patients seeking to manage their condition and prevent relapses.

Date :
  1. Date Completed 2016-12-13
  2. Date Revised 2016-12-30
Further Info :

Pubmed ID

26368296

DOI: Digital Object Identifier

10.1097/MCG.0000000000000414

Related Literature

Article Analysis
・Effects of mesalamine rectal
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.